TNF-α induces the overexpression of programmed death ligand 1 (PD-L1) in a variety of tumors, creates an immunosuppressive TME, weakens the inhibitory effect of immune checkpoints, and induces tumor cells to develop resistance to targeted therapy (18). This evidence concerns the gene TNF and neoplasm.